Bharat Dixit - Artugen Therapeutics
Adrien Nivoliez - Biose Industrie
Sarah Garant - Seres Therapeutics, Inc
• Understand how our speakers are controlling the costs of goods for LBPs in phase 1 and 2.
• Assess the latest methods to avoid pathogen presence in final LBP product.
• In-house or CDMO? With manufacturing not being a core competency of microbiome companies, what are the implications of both business models and which is best for your company?
• How can you implement better analytics for quality control (including PCR and flow cytometry) to replace classical approaches like microscopy and CFU count?